Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
India has many cities that are famous for their unique industries, and some of them…
Some deserts are extremely hot, but some remain cold throughout the year. These cold deserts…
In today’s world, news media plays a very important role in sharing information quickly and…
PNB Housing Finance has announced the appointment of Ajai Kumar Shukla as its new Managing…
In a major push towards deepening financial inclusion, the Department of Posts (DoP) and BSE,…
India’s retail inflation, measured by the Consumer Price Index (CPI), increased modestly to 0.71% in…